• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Clinical phenotypes and quality of life to define post-COVID-19 syndrome: a cluster analysis of the multinational, prospective ORCHESTRA cohort
EClinicalMedicine. 2023 Jul 21;62:102107. doi: 10.1016/j.eclinm.2023.102107. eCollection 2023 Aug.ABSTRACTBACKGROUND: Lack of specific definitions of clinical characteristics, disease severity, and risk and preventive factors of post-COVID-19 syndrome (PCS) severely impacts research and discovery of new preventive and therapeutics drugs.METHODS: This prospective multicenter cohort study was conducted from February 2020 to June 2022 in 5 countries, enrolling SARS-CoV-2 out- and in-patients followed at 3-, 6-, and 12-month from diagnosis, with assessment of clinical and biochemical features, antibody (Ab) response, Variant o...
Source: Cell Research - September 1, 2023 Category: Cytology Authors: Elisa Gentilotti Anna G órska Adriana Tami Roy Gusinow Massimo Mirandola Jes ús Rodríguez Baño Zaira R Palacios Baena Elisa Rossi Jan Hasenauer Iris Lopes-Rafegas Elda Righi Natascia Caroccia Salvatore Cataudella Zeno Pasquini Thomas Osmo Lidia Del Pi Source Type: research

Corticosteroids and Severe Community-acquired Pneumonia: New Data, New Questions and a Swinging Pendulum
Arch Bronconeumol. 2023 Aug 16:S0300-2896(23)00278-8. doi: 10.1016/j.arbres.2023.08.005. Online ahead of print.NO ABSTRACTPMID:37625907 | DOI:10.1016/j.arbres.2023.08.005
Source: Archivos de Bronconeumologia - August 25, 2023 Category: Respiratory Medicine Authors: Grant W Waterer Mark Metersky Source Type: research

Duchenne muscular dystrophy: Current treatment and emerging exon skipping and gene therapy approach
Eur J Pharmacol. 2023 Mar 22:175675. doi: 10.1016/j.ejphar.2023.175675. Online ahead of print.ABSTRACTDuchenne muscular dystrophy (DMD) is an X-linked recessive neuromuscular disorder that causes debilitating muscle weakness and atrophy due to a loss of the dystrophin protein. Patients with DMD are commonly diagnosed at about 3-5 years of age and progressively decline until complications of the disease often result in death at about 20 years of age. While there is no current cure for DMD, several treatment options focus on improving the quality of life and slowing progression of symptoms associated with the disease. The cu...
Source: European Journal of Pharmacology - March 24, 2023 Category: Drugs & Pharmacology Authors: Grant Patterson Haley Conner Mecham Groneman Cyril Blavo Mayur S Parmar Source Type: research

Use of digital measurement of medication adherence and lung function to guide the management of uncontrolled asthma (INCA Sun): a multicentre, single-blinded, randomised clinical trial
Lancet Respir Med. 2023 Mar 21:S2213-2600(22)00534-3. doi: 10.1016/S2213-2600(22)00534-3. Online ahead of print.ABSTRACTBACKGROUND: The clinical value of using digital tools to assess adherence and lung function in uncontrolled asthma is not known. We aimed to compare treatment decisions guided by digitally acquired data on adherence, inhaler technique, and peak flow with existing methods.METHODS: A 32-week prospective, multicentre, single-blinded, parallel, randomly controlled trial was done in ten severe asthma clinics across Ireland, Northern Ireland, and England. Participants were 18 years or older, had uncontrolled as...
Source: Respiratory Care - March 24, 2023 Category: Respiratory Medicine Authors: Elaine Mac Hale Garrett Greene Christopher Mulvey Matshediso C Mokoka Job F M van Boven Breda Cushen Imran Sulaiman Vincent Brennan Patrick J Kerr Richard B Reilly Cian Hughes Brian D Kent David J Jackson Marcus Butler Ian Counihan James Hayes John Faul M Source Type: research

Safety of SABA Monotherapy in Asthma Management: a Systematic Review and Meta-analysis
CONCLUSIONS: Meta-analysis of data from RCTs showed that deaths were rare with SABA reliever monotherapy, and rates of SAEs and DAEs were comparable between SABA reliever and ICS treatment groups. When used appropriately within prescribed limits as reliever therapy, SABA does not contribute to excess rates of mortality, SAEs, or DAEs.PMID:36348141 | DOI:10.1007/s12325-022-02356-2
Source: Adv Data - November 8, 2022 Category: Epidemiology Authors: Thitiwat Sriprasart Grant Waterer Gabriel Garcia Adalberto Rubin Marco Antonio Loustaunau Andrade Agnieszka Roguska Abhay Phansalkar Sourabh Fulmali Amber Martin Lalith Mittal Bhumika Aggarwal Gur Levy Source Type: research

Symptom Duration and Diabetic Control Influence Success of Steroid Injection in Trigger Finger
CONCLUSIONS: Patients with a co-existing diagnosis of diabetes and an A1c greater than 6.5, ipsilateral concomitant hand disease, or presence of symptoms for greater than 2.5 months should be counseled regarding higher risk of failure of local corticosteroid injection.PMID:35671444 | DOI:10.1097/PRS.0000000000009320
Source: Hand Surgery - June 7, 2022 Category: Surgery Authors: Andrew W Hollins Rachel Hein Andrew Atia Mahsa Taskindoust Grant Darner Ronnie Shammas Suhail K Mithani Source Type: research

Clinical outcomes after IL-6 blockade in patients with COVID-19 and HIV: a case series
CONCLUSIONS: In this case series of hospitalized PWH with COVID-19 and given IL-6ri prior to the common use of corticosteroids, there are reports of secondary or co-infection in severely ill patients. Comprehensive studies in PWH, particularly with CD4 counts < 200 cells, are warranted to assess infectious and other outcomes after IL-6ri use, particularly in the context of co-administered corticosteroids.PMID:35148782 | DOI:10.1186/s12981-022-00430-x
Source: AIDS Research and Therapy - February 12, 2022 Category: Infectious Diseases Authors: Samuel J Minkove Grant Geiger Josep M Llibre Mary W Montgomery Natalie E West Natasha M Chida Annukka A R Antar Dima Dandachi Ethel D Weld HIV-COVID-19 Consortium Source Type: research

The Steroid Therapy and Outcome of Parapneumonic Pleural Effusions (STOPPE): A Pilot Randomized Trial
CONCLUSIONS: Systemic corticosteroids showed no preliminary benefits in adults with parapneumonic effusions. Clinical trial registration available at https://anzctr.org.au/, ID: ACTRN12618000947202.PMID:35081010 | DOI:10.1164/rccm.202107-1600OC
Source: Am J Respir Crit Car... - January 26, 2022 Category: Intensive Care Authors: Deirdre B Fitzgerald Grant W Waterer Charley Budgeon Ranjan Shrestha Edward T Fysh Sanjeevan Muruganandan Christopher Stanley Tajalli Saghaie Arash Badiei Calvin Sidhu Hilman Harryanto Victor Duong Maree Azzopardi David Manners Norris S H Lan Natalia D Po Source Type: research

COVID-19 and Cytokine Storm Syndrome: Are there lessons from Macrophage Activation Syndrome?
Transl Res. 2021 Mar 5:S1931-5244(21)00052-9. doi: 10.1016/j.trsl.2021.03.002. Online ahead of print.ABSTRACTAlthough interest in "cytokine storms" has surged over the past decade, it was massively amplified in 2020 when it was suggested that a subset of patients with COVID-19 developed a form of cytokine storm. The concept of cytokine storm syndromes (CSS) encompasses diverse conditions or circumstances that coalesce around potentially lethal hyperinflammation with hemodynamic compromise and multiple organ dysfunction syndrome. Macrophage activation syndrome (MAS) is a prototypic form of CSS that develops in the context o...
Source: Translational Research : the journal of laboratory and clinical medicine - March 8, 2021 Category: Laboratory Medicine Authors: Michael J Ombrello Grant S Schulert Source Type: research

Pages: 1  2